$PYPD News

PolyPid Completes Its New Drug Application Submission On Rolling Review Basis Top FDA For D-PLEX100 To Prevent Surgical Site Infections

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

PolyPid (PYPD) Q1 2026 Earnings Transcript

PolyPid Q1 Earnings Call Highlights

PolyPid Q1 2026 Earnings Call: Complete Transcript

PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PolyPid Q1 2026 Earnings Call: Complete Transcript

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid To Present ASEPSIS Analysis Data From Its Phase 3 SHIELD II Study Of D-PLEX At 5th Annual Meeting Of The Surgical Infection Society

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Initiates New Drug Application With FDA For D-PLEX₁₀₀ For Prevention Of Colorectal Surgical Site Infections

PolyPid Initiates New Drug Application With FDA For D-PLEX₁₀₀ For Prevention Of Colorectal Surgical Site Infections

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application

PolyPid Receives Small Business Waiver From FDA For $4.3M PDUFA Fee For New Drug Application For D-PLEX₁₀₀ Colorectal Surgery Infection Prevention Treatment

PolyPid Announces Participation in Upcoming Investor Conferences